Skin and Ocular Irritation Alternatives Patents: Who Leads 2026
Skin and Ocular Irritation Alternative Test Method Patents
Filings jumped from 1 in 2021 to 10 in 2024, a +900% rise over three years, right as non-animal test methods gained regulatory traction. Filings were flat near zero through the late 2010s, then rose sharply: 2021 recorded 1 filing, 2024 recorded 10 — the peak year so far, a +900% increase across that span. Because publication trails filing by roughly 18 months, the 2025 and 2026 figures are still incomplete and should not be read as a slowdown.
- 1LEBRUN LABS LLC14
- 2LANKEM LTD4
- 3BENAKI PHYTOPATHOLOGICAL INST1
- 4ZINGKOU ELENI1
- 5EMRIS PHARMA LTD1
See the full skin and ocular irritation alternatives analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions about this landscape
How many patents exist for skin and ocular irritation alternative test methods?
This landscape tracks 20 patent families published between 2015 and the 2026-07-31 data cut-off, matching search terms around reconstructed human epidermis, ocular irritation testing and skin sensitization assays combined with terms like barrier function control and prediction model. That is a small, specialised field rather than a broad one. Because publication lags filing by roughly 18 months, the true count for 2025 and 2026 filings will rise as more applications publish.
Who are the leading patent holders in non-animal irritation testing?
The ranked list covers 11 companies, and it is heavily front-loaded: the leading assignee holds 14 of the 20 ranked families, built around in chemico toxicity testing using enzyme-activity readouts. The fifth-ranked and tenth-ranked assignees each hold just 1 family, meaning most of the remaining organisations are single-filing research institutes, universities or individual inventors rather than sustained corporate programmes.
Is filing activity in this field growing or slowing down?
Filings grew sharply, from 1 family in 2021 to 10 in 2024, a +900% increase over that three-year span and the field’s peak year to date. Figures for 2025 and 2026 appear lower, but that reflects the normal 18-month lag between filing and publication rather than a genuine slowdown. Treat any recent-year dip in this dataset as incomplete data, not a trend reversal.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Skin and Ocular Irritation Alternatives covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.